Recent 8-K filings for INBP

• September 25, 2026, 5:05 PM ET earnings materiality 0.60 negative item 2.02item 9.01

  Integrated BioPharma FY2026 revenue falls 19.3% to $43.9M; swings to $2.8M net loss from $0.8M income

  Q4 revenue $9.8M vs $14.2M a year earlier, down $4.4M or 31.0%; Q4 operating loss $0.9M vs $0.6M operating income.

• May 8, 2026, 7:59 PM ET earnings materiality 0.75 negative item 2.02item 9.01 ◈ Earnings Releases ×2

  Integrated BioPharma reports Q3 net loss of $0.8M, revenue falls 27.3% to $10.1M

  Net loss $0.8M ($0.03 loss per share) vs net income $0.6M ($0.02 EPS) in Q3 2025.

• February 11, 2026, 6:59 PM ET earnings materiality 0.70 negative item 2.02item 9.01

  Integrated BioPharma Q2 revenue down 10.3%, swings to net loss of $0.8M

  Revenue $11.3M vs $12.6M Q2 prior year; operating loss $0.9M vs income $0.2M.

• September 23, 2025, 7:59 PM ET earnings materiality 0.60 neutral item 2.02item 9.01

  Integrated BioPharma Q4 rev $14.2M (+11.8%); net loss $0.2M on tax; FY net income $808k

  Q4 revenue $14.2M vs $12.7M (+11.8%); operating income $589k vs $402k.

• April 21, 2025, 7:59 PM ET debt materiality 0.60 neutral item 1.02item 1.01item 2.03item 9.01 ◈ Debt Financings ×2

  Integrated BioPharma enters $4.5M PNC credit facility; replaces prior debt

  New $4M revolving line of credit and $500K convertible equipment line from PNC Bank (SOFR+250bps).

• February 12, 2024, 6:59 PM ET earnings materiality 0.60 negative item 2.02item 9.01 ◈ Earnings Releases

  Integrated BioPharma Q2 revenue down 6.5% to $11.5M; net loss widens to $0.4M

  Revenue $11.5M vs $12.3M in prior-year quarter (-6.5%).

• September 15, 2023, 7:59 PM ET earnings materiality 0.65 negative item 2.02item 9.01 ◈ Earnings Releases ×2

  Integrated BioPharma FY2023 revenue down 9.8%; net loss of $34K vs prior year net income $3.8M

  Q4 revenue $13.0M (-2.3% YoY); operating income $79K vs $438K; net income $40K ($0.00 EPS).

• May 11, 2023, 7:59 PM ET earnings materiality 0.65 negative item 2.02item 9.01 ◈ Earnings Releases

  Integrated BioPharma Q3 revenue down 16% YoY; net income falls to $16K from $0.8M

  Quarterly revenue $13.1M, down 16.2% from $15.6M in prior year.

• March 21, 2023, 7:59 PM ET leadership materiality 0.75 negative item 8.01item 9.01

  Integrated BioPharma founder, Executive Chairman & President Edward G. Kay dies at 86

  Edward G. Kay, founder, Executive Chairman and President, passed away on March 20, 2023, at age 86.

• February 10, 2023, 6:59 PM ET earnings materiality 0.60 negative item 2.02item 9.01 ◈ Earnings Releases ×2

  Integrated BioPharma Q2 revenue falls 15.6% YoY; swings to net loss of $55K

  Revenue $12.3M vs $14.6M a year ago; operating loss ~$33K vs income $0.7M.

• November 14, 2022, 6:59 PM ET earnings materiality 0.60 negative item 2.02item 9.01 ◈ Earnings Releases

  Integrated BioPharma Q1 net loss of $35K vs net income $516K YoY; revenue down 3% to $12.3M

  Revenue $12.3M, down ~3.1% from $12.8M in Q1 FY2022.

• September 14, 2022, 7:59 PM ET earnings materiality 0.65 negative item 2.02item 9.01

  Integrated BioPharma Q4 FY22 net income $1.5M, down 67% YoY; revenue falls 22%

  Q4 revenue $13.3M, down 22.2% from $17.1M; operating income $0.4M vs $1.3M.

• February 10, 2022, 6:59 PM ET earnings materiality 0.60 negative item 2.02item 9.01

  Integrated BioPharma (INBP) Q1 net income $1.0M vs $1.2M; revenue up 2.1%

  Revenue for quarter ended Dec 31, 2021: $14.6M, up 2.1% YoY from $14.3M.

Earnings & guidance

Materiality & sentiment trend

Max materiality 0.75 · Median 0.50 · Most common event earnings

5 positive 15 negative 20 neutral

source · INBP on sec.gov